Kurma Partners | Biofund IV
◆ Fund Size
$215M
◆ Check Size
◆ Location
France
◆ Portfolio
40 companies
◆ Activity
Statusactively investing
◆ Links
◆ Share this fund
◆ Investment Thesis
Support European biotech startups with specialist pool of capital
◆ About Kurma Partners
Kurma Biofund IV is a €215 million venture capital fund managed by Kurma Partners, dedicated to investing in innovative therapeutics addressing diseases with high medical needs, primarily in life sciences and biotechnology. It focuses 80% of investments on therapeutic approaches, including company creations and venture-stage companies, with up to 50% allocated to firms established by Kurma or Argobio. The fund targets 16-20 investments across Europe and beyond, leveraging academic science and industry networks.[1][2][3]
◆ Sectors
◆ Stages
◆ Geography Focus
◆ Team
| Name | Title | Role | Links |
|---|---|---|---|
| Alain Horvais | Partner, Diagnostic | — | in |
| Amanda Gett | Partner, Biofund | — | |
| Daniel Parera | Partner, Germany / Growth Opportunities | — | in |
| Hadrien Bouchez | Partner, Biofund | — | in𝕏 |
| Jean-François | Partner, Growth Opportunities | — | |
| Peter Neubeck | Partner, Germany / Biofund | — | |
| Rémi Droller | Managing Partner, Biofund | — | |
| Thierry Laugel | Managing Partner, Biofund | — |
◆ Notable Investments
◆ Traits
Leads rounds
Co-invests
◆ FAQ
What does Biofund IV invest in?
Biofund IV invests in Biotech at the seed and series-a stages.
Which geographies does Biofund IV focus on?
Biofund IV focuses on Europe, and is headquartered in France.
What is Biofund IV's typical check size?
Biofund IV typically writes checks of $1M to $15M.